Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03468855 · ClinicalTrials.gov registry record · Phase 2
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
A Phase 2 study of Vitiligo, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 5
- Study locations
NCT03468855: Completed Phase 2 study of Vitiligo, sponsored by Aclaris Therapeutics.
NCT03468855 is a Phase 2 study of Vitiligo that has completed, run by Aclaris Therapeutics. The registered enrollment target is 34 participants, below the 1,122-participant average among 15 other Vitiligo trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03468855, a Phase 2 study of Vitiligo, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
Primary Outcome
Mean change from baseline in facial depigmentation in quantified Area of Interest (AOI) using Canfield-2-D photographic image analysis from baseline (Visit 2) compared to Week 24. Facial depigmentation is measured on a scale of 0 to 100, with a score of 0 meaning no depigmentation and a score of 100 meaning total depigmentation. Lower scores represent better outcomes.
Conditions Studied
Interventions
- DRUG ATI-50002 topical solution
Study Locations (5)
California
- Aclaris Investigator Site - Encinitas
- Aclaris Investigator Site - Los Angeles
Massachusetts
- Aclaris Investigator Site - Worcester
Texas
- Aclaris Investigator Site - Dallas
Virginia
- Aclaris Investigator Site - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2019-10-16 |
| Phase | Phase 2 |
What the finished NCT03468855 record still lists
NCT03468855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,122-participant average among 15 other Vitiligo trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 1 intervention - of which ATI-50002 topical solution is the first listed.
NCT03468855 lists 5 locations in 4 states (California, Massachusetts, Texas).
Frequently Asked Questions
What is clinical trial NCT03468855 about?
NCT03468855 is a clinical study titled "A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo". The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
What is the current status of trial NCT03468855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2018-03-19. Estimated completion is 2019-10-16.
What conditions does trial NCT03468855 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT03468855?
The interventions under investigation include: ATI-50002 topical solution (DRUG).
Who is sponsoring clinical trial NCT03468855?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03468855 being conducted?
This trial has 5 study locations across California, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03468855's enrollment target sits among peer trials
34 11th of 15 higher than 5 of 15 other Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Daily Topical Rapamycin for Vitiligo
ACTIVE NOT RECRUITING · Phase 2
-
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
COMPLETED · Phase 2
-
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
COMPLETED · Phase 2
-
Evaluation of AMG 714 for Vitiligo
COMPLETED · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI